2010 full-year results 3 March 2011 - UCB
2010 full-year results 3 March 2011 - UCB
2010 full-year results 3 March 2011 - UCB
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Olokizumab (CDP6038, anti-IL-6) in rheumatoid arthritis<br />
Phase 2b programme started – <strong>results</strong> Q3 2012<br />
Phase 2b trial currently recruiting<br />
• Active RA having previously failed TNF blocker therapy<br />
• 220 patients across approximately 100 sites in U.S. and<br />
Europe<br />
• Randomised, double-blind placebo-controlled, doseranging<br />
study with an active comparator (Actemra ® iv) to<br />
evaluate efficacy and safety of olokizumab<br />
• 3 dose levels of OZK administered sc, every 2 or 4 weeks<br />
• 12 weeks treatment duration plus open-label extension<br />
Primary endpoint<br />
Olokizumab<br />
Rheumatoid arthritis<br />
Phase 1 Phase 2<br />
Results<br />
Q3 2012<br />
Stephanie, living with<br />
rheumatoid arthritis<br />
To evaluate the clinical efficacy by the change from baseline in the Disease Activity<br />
Score for olokizumab and placebo at week 12<br />
70
Change language